Samsung Biologics (KRX:207940) signed three biologics contract manufacturing organization (CMO) contracts with undisclosed European pharmaceutical companies.
The contracts, valued at 56.7 billion won, 56.1 billion won, and 1.110 trillion won, are all valid until Dec. 31, 2030.
Shares of Samsung Biologics fell nearly 1% in Monday morning trade.